Shots:
Recently, the groundbreaking results from Galderma’s Phase III OLYMPIA 1 trial were published in JAMA Dermatology. The study evaluated nemolizumab in patients with moderate-to-severe active prurigo nodularis
The trial met all primary and secondary endpoints, with results aligning with those from the OLYMPIA 2 trial, reinforcing nemolizumab’s potential in achieving sustained improvements in the…
Shots:
Driven by continuous innovation, the MedTech sector is evolving rapidly to enhance preventive, diagnostic, and therapeutic capabilities in healthcare
In 2023, the global MedTech market was valued at $668.2B and is projected to reach $989.1B by 2033, growing at a CAGR of approximately 4%. Medtronic led the industry with a revenue of $33.12B, followed…
Shots:
Identifying discrepancies remains a key challenge for manufacturers in mitigating revenue leakage and ensuring alignment with payer plans
Suresh Kannan, Model N’s Chief Product Officer, offers insights into the newly launched GenAI and enhanced data solutions aimed at optimizing revenue and ensuring compliance
He also outlines a strategic approach to formulary identification and emphasizes…
Shots:
The EMA’s CHMP has granted positive opinions and approvals to 4 Biologics and 4 New Chemical Entites in April 2025, leading to treatments for patients and advances in the healthcare industry
The major highlighted drugs were Amgen’s Tepezza to Treat Thyroid Eye Disease
PharmaShots has compiled a list of 8 drugs that have been granted positive opinions…
Shots:
Research into Lupus has yielded groundbreaking results in pharmacokinetics and pharmacodynamics, yet experts still don't understand its cause
Lupus Research Alliance (LRA) recently launched a platform called Data Repository, Exchange, and Analytics (DREAM) for data sharing and partnerships for research in lupus
Devon Kelly, Director of Lupus Nexus at the Lupus Research Alliance, sheds…
Shots:
Welcome to the 2025 edition of Know Your Investor, spotlighting leading venture capital firms driving innovation in healthcare.
This edition features Alexandria Venture Investments, a firm committed to supporting disruptive life science companies that aim to improve human health.
In 2024, the firm invested approximately $2.7B across six public and private funding rounds, adding…
Shots:
PharmaShots has compiled a list of US FDA-approved drugs in the month of April 2025
The US FDA has approved a total of 3 new drug including 1 new molecular entity and 2 Biologics leading to the treatment of patients and advances in the healthcare industry
The major highlighted drug was Johnson & Johnson’s…
In the CXO Talks podcast, PharmaShots engaged in a riveting dialogue exchange with Colin Banas, Chief Medical Officer at DrFirst. Colin highlights the evolution of DrFirst from becoming a leader in the e-prescribing space to an end-to-end medication management company
Colin talks about its collaborators, Wise Hospice Options, achieving a new milestone by reducing the…
The field of orthodontics is undergoing a significant transformation, driven by cutting-edge technologies and patient-centric approaches. Innovations in this area are not only enhancing treatment outcomes but also revolutionizing the overall patient experience. As these advancements continue to evolve, they are shaping the future landscape of orthodontic care.
The evolving landscape of orthodontic care is…
The integration of tele-orthodontics into healthcare marks a significant shift in how dental care is delivered. Digital platforms are revolutionizing the patient experience, providing unprecedented access to orthodontic expertise. As technology advances, understanding its impact on patient outcomes is crucial.
Tele-orthodontics is rapidly becoming a staple in modern healthcare, reflecting a broader trend towards telemedicine.…

